bioRxiv Science⌕ Search

bioRxiv · 10.1101/2025.02.16.638550

Targeted knockdown of in vitro candidates does not alter Wolbachia density in vivo

Abstract

The bacterial endosymbiont Wolbachia has emerged as an effective biocontrol method to reduce arbovirus transmission. Transinfection of wMel Wolbachia from Drosophila melanogaster to Aedes aegypti results in the transfer of important Wolbachia-induced phenotypes including the reproductive modification, cytoplasmic incompatibility, and inhibition of viruses including dengue and chikungunya. However, the mechanisms underlying these critical traits as well other Wolbachia-host interactions are still not fully understood. Recently an in vitro genome wide RNAi screen was performed on wMel-infected Drosophila S2 cells and identified large cohorts of host genes that alter wMel density when targeted. If these findings can be replicated in vivo, this would provide a powerful tool for modulating wMel density both systemically and in a tissue-specific manner allowing for interrogation of wMel-host interactions. Here, we used the GAL4/UAS system to express RNAi molecules targeting host gene candidates previously identified to dysregulate wMel density in vitro. We found systemic knockdown of two candidate D. melanogaster genes does not lead to wMel density dysregulation. To explore the lack of consistency between our study and previous work, we also examined native tissue-specific density of wMel in D. melanogaster. We show density is varied between tissues and find that individual tissue densities are not reliable linear predictors of other tissue densities. Our results demonstrate the complexities of implementing in vitro findings in systemic applications.

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Dainty, K. R., Duyvestyn, J. M., Flores, H. A.. 2025-02-21. Targeted knockdown of in vitro candidates does not alter Wolbachia density in vivo. https://doi.org/10.1101/2025.02.16.638550

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

OPA1 controls mitochondrial dysfunction-driven liver fibrosis in MASLD

Progressive hepatic fibrosis is the principal determinant of morbidity and mortality in metabolic dysfunction-associated steatotic liver disease and steatohepatitis (MASLD/MASH). Mitochondrial dysfunction is a hallmark of MASH, and the release of mitochondrial damage-associated molecular patterns (mito-DAMPs) from injured hepatocytes can promote fibrosis. However, how mitochondrial dynamics and quality control shape the fibrotic response in MASLD/MASH remains unclear. Here, through large-scale genomic analyses of mitochondrial genes governing mitophagy, fusion and fission in human MASLD, with a power-equivalent sample size of approximately 700,000 individuals, we identify a strong association between hepatic fibrosis and the mitochondrial fusion factor dynamin-like GTPase optic atrophy 1 (OPA1). OPA1 transcripts and protein abundance in the liver epithelium were progressively dysregulated with advancing fibrosis. In mice, hepatocyte-specific OPA1 loss alone was sufficient to induce hepatic stellate cell activation and fibrosis in zone 3, promoted the release of mito-DAMPs into the circulation and exacerbated fibrosis in experimental MASH. These findings identify OPA1 as a central regulator of the hepatic fibrotic response and connect defective mitochondrial homeostasis to mito-DAMP release, hepatic stellate cell activation and fibrosis in MASLD.

genetics↗

Mechanism-selective deep mutational scanning distinguishes ERCC2 disease phenotypes

Pathogenic ERCC2 variants cause xeroderma pigmentosum (XP), trichothiodystrophy (TTD) or both, yet variant effect scores are usually interpreted only as measures of pathogenicity rather than of which disease mechanism is disrupted. XPD, the ERCC2-encoded TFIIH subunit, functions in both nucleotide excision repair and transcription. Using yeast complementation deep mutational scanning, we measured the effects of nearly all XPD amino acid substitutions. The assay was mechanism-selective: it preferentially reported transcription-associated function, with pronounced intolerance at the p44 interface, whereas many substitutions affecting DNA binding and helicase activity retained near-wild-type fitness. Accordingly, TTD variants had much lower fitness than XP variants. Computational predictors discriminated pathogenic from benign variants similarly across phenotypes, but the DMS distinguished XP from TTD variants better than all 73 predictors tested. Phenotype-specific ACMG/AMP calibration provided evidence in both directions for TTD but mainly pathogenic evidence for XP. Thus, the selectivity of functional assays, often viewed as a limitation, can reveal disease mechanisms and support phenotype-aware variant interpretation.

genetics↗

Temporal control of mitochondrial mutagenesis reveals the fate of mtDNA mutations with age

Mutations in the mitochondrial genome (mtDNA) play a critical role in the aging process and a wide variety of age-related diseases. However, it remains unclear when the mutations that drive physiological decline arise. To answer this question, we generated a new mouse model in which mitochondrial mutagenesis can be confined to a defined window of time. Surprisingly, we found that mutations that arise during the first two months of life are sufficient to drive a wide variety of age-related pathologies, and that the severity of this pathology is broadly regulated by distinct, tissue-specific selective pressures that control the fate of mtDNA mutations with age. Further, we found that selection against deleterious variants can be modulated by manipulation of mitochondrial fusion in vitro and in vivo. These observations raise the possibility that in some tissues, the pace of aging is pre-determined by events that occur early in life and that interventions targeting mitochondrial fusion may be able to slow down or reverse the expansion of these pathogenic variants. These results carry far-reaching implications for strategies aimed at preventing or delaying age-related decline.

genetics↗